An innovated approach to in vivo screening for the major anti-cancer drugs

Horizons in Cancer Research

Volumn 41, Issue , 2010, Pages 249-259

  Maruta, Hiroshi ^a  

^a NF Cure Japan   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85008741692     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (26)

1. Stehelin, D., Varmus, H., Bishop, M. & Vogt, P. (1976). DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature, 260, 170-173.
2. Koblan, K. & Kohl, N. (1998). Farnesyltransferase inhibitors: agents for the treatment of human cancer. In G., proteins, Cytoskeleton, Cancer (H., Maruta, K. Kohama, Eds.), 291-302, Landes Bioscience, Austin.
3. Bos, J. (1989). Ras oncogenes in human cancer: A review. Cancer Res., 49, 4682-4689.
4. Buchdunger, E., Zimmermann, J., Mett, H. & Meyer, M., et al (1996). Inhibition of Abl Tyr-kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 56, 100-104.
5. Nowell, P. & Hungerford, D. (1960). A minute chromosome in chronic granulocytic leukemia. Science, 132, 1497.
6. Swaisland, H., Laight, A., Stafford, L. & Jones, H., et al. (2001). Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet, 40, 297-306.
7. Ueda, M., Manda, T. & Matsumoto, S., et al. (1994). FK228, a novel antitumor bicyclic depsipeptide produced by C. vialaceum No. 968. II. Antitumor activitities on experimental tumors in mice. J. Antibiot, 47, 311-314.
8. Nakajima, H., Kim, Y. B. & Terano, H., et al (1998). FK228, a potent antitumor antibiotoc, is a novel histone deacetylase inhibitor. Exp. Cell Res., 241, 126-133.
9. Hirokawa, Y., Arnold, M., Nakajima, H., Zalcberg, J. & Maruta, H. (2005). Signal therapy of breast cancer xenograft in mice by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol. Ther., 4, 956-960.
10. Demestre, M., Messerli, S., Celli, N. & Shahhossini, M., et al. (2009). CAPE (Caffeic Acid Phenethyl Ester)-based Propolis Extract (Bio 30) Suppresses the Growth of Human Neurofibromatosis (NF) Tumor Xenografts in Mice. Phytother. Res., 23, 226-230.
11. Hashimoto, H., Sudo, T., Maruta, H. & Nishimura, R. (2009). The direct PAK1 inhibitor, TAT-PAK18, blocks preferentially the growth of human ovarian cancer cell lines in which PAK1 is abnormally activated by autophosphorylation at Thr 423. Drug Discov. Ther., in press.
12. Messerli, S., Ahn, M. R., Kunimasa, K., Yanagihara, M., Tatefuji, T., Hashimoto, K., Kluwe, L., Mautner, V., Uto, Y., Hori, H., Kumazawa, S., Kaji, K., Ohta, T. & Maruta, H. (2009). Artepillin C (ARC) in Brazilian Green Propolis Selectively Blocks the Oncogenic PAK1 Signaling and Suppresses the Growth of NF Tumors in Mice. Phytother. Res., 23, 423-427.
13. Sudo, T., Messerli, S. & Maruta, H., et al. (2009). Hashimoto, H., Messerli, S., Sudo, T. & Maruta, H. (2009). Ivermectin Inactivates the Kinase PAK1 and Block the PAK1- dependent Growth of Human Ovarian Cancer and NF2 Tumor Cell Lines. Drug Discov. Ther., in press.
14. Shibayama-Imazu, T., Sakairi, S., Watanabe, A. & Aiuchi, T., et al. (2003). Vitamin K2 selectively induced apoptosis in ovarian TYK-nu and pancreatic MIAPaCa-2 cells through a mechanism different from geranylgeraniol. J. Cancer Res. Clin. Oncol, 129, 1-11.
15. Liu, W., Nakamura, H., Yamamoto, T. & Ikeda, N., et al. (2007). Vitamin K2 inhibits the proliferation of HepG2 cells by up-regulating the transcription of p21 gene. Hepatol Res., 37, 360-5.
16. Otsuka, M., Kato, N., Shao, R. X. & Hoshida, Y., et al (2004). Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology, 40, 243-51.
17. Ma, M., Qu, X. J., Mu, G. Y. & Chen, M. H., et al (2009). Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gamma-carboxy prothrombin. Chemotherapy, 55, 28-35.
18. Hayashi, M. L., Rao, B. S., Seo, J. S. & Choi, H. S, et al (2007). Inhibition of p21- activated kinase rescues symptoms of fragile X syndrome in mice. Proc Natl Acad Sci U S A. 104, 11489-94.
19. Nguyen, D. G., Wolff, K. C., Yin, H. & Caldwell, J. S., et al (2006). "UnPAKing" human immunodeficiency virus (HIV) replication: using small interfering RNA screening to identify novel cofactors and elucidate the role of group I PAKs in HIV infection. J Virol, 80, 130-7.
20. Allen, J. D., Jaffer, Z. M., Park, S. J., Burgin, S. & Hofmann, C., et al (2009). PAK1 regulates mast cell degranulation via effects on calcium mobilization and cytoskeletal dynamics. Blood, in press.
21. Manser, E., Leung, T. & Salihuddin, H., et al. (1994). A brain Ser/Thr-kinase activated by CDC42 and Rac 1. Nature, 267, 40-46.
22. Maruta, H., Korn, ED. (1977). Acanthamoeba cofactor protein is a heavy chain kinase for actin activation of the Mg2+-ATPase activity of Acanthamoeba myosin I. J. Biol. Chem. 252, 8329-8332.
23. Chen W, Chen S, Yap SF, Lim L. (1996). The C. elegans PAK1 (CePAK) colocalizes with Rac1 and CDC42 at hypodermal cell boundaries during embryo elongation. J Biol Chem. 271: 26362-8.
24. Walker GA, White TM, McColl G, Jenkins NL, et al (2001). Heat shock protein accumulation is upregulated in a long-lived mutant of C. elegans. J Gerontol A Biol Sci Med Sci. 56: B281-7.
25. Engelberg D, Zandi E, Parker CS, Karin M. (1994). The yeast and mammalian Ras pathways control transcription of heat shock genes independently of heat shock transcription factor. Mol Cell Biol. 14: 4929-37.
26. Hara M, Han M. (1995). RAS farnesyltransferase inhibitors suppress the phenotype resulting from an activated RAS mutation in C. elegans. Proc Natl Acad Sci U S A. 92: 3333-7.